Q4 2025 · 13F-HR
B Group, Inc.holdings as filed
Filed 2026-02-17 · accession 0001420506-26-000462
$135.4M
Reported value
16
Positions
2025-12-31
Period end
The Brief · B Group, Inc. · Q4 2025
AI · grounded in 13F
B Group, Inc. exited its position in LLY for a reduction of $17.17M. The fund also closed positions in NVDA and AKRO, reducing holdings by $13.99M and $11.04M respectively. To offset these exits, the fund established new positions in PALI for $10.58M and GPCR for $6.26M. Additionally, the fund increased its share counts in PRAX by 5.51% and ADMA by 1.87%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 000899104 | ADMA | ADMA BIOLOGICS INC | $44.8M | 33.1% | 2,457,542 | Common | SOLE |
| 15117K103 | CLLS | CELLECTIS S A | $15.9M | 11.7% | 3,281,501 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $10.6M | 7.81% | 4,500,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $9.9M | 7.31% | 1,800,556 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $9.8M | 7.23% | 33,237 | Common | SOLE |
| 82657M105 | SGHT | SIGHT SCIENCES INC | $7.3M | 5.39% | 920,000 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $7.1M | 5.21% | 400,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $6.3M | 4.62% | 90,000 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $6.0M | 4.41% | 175,706 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $4.1M | 3.02% | 1,500,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $3.3M | 2.42% | 100,000 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $3.1M | 2.30% | 572,576 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $3.1M | 2.29% | 135,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $2.3M | 1.68% | 75,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $1.5M | 1.11% | 20,000 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $486,000 | 0.36% | 50,000 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.